Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
85 hedge funds and large institutions have $39M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 24 closing their positions.
50% more call options, than puts
Call options by funds: $9K | Put options by funds: $6K
17% less funds holding
Funds holding: 102 → 85 (-17)
17% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 30
58% less capital invested
Capital invested by funds: $92.7M → $39M (-$53.7M)
58% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 24
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.65M |
| 2 |
Millennium Management
New York
|
+$2.6M |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$868K |
| 4 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
+$506K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$425K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.34M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$2.69M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.06M |
| 4 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$1.15M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.09M |
JNCE Hedge Fund Activity: Q4 2022 in Review
85 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2022, worth a combined $39M — down 58% from $92.7M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of JNCE and 10 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 25 added.
The largest buyer was Bank of America, adding an estimated $4.65M. The largest seller was PFM Health Sciences, cutting an estimated $5.34M.
- 85 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2022, down from 102 in Q3 2022.
- Funds reported $39M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2022, down 58% quarter-over-quarter.
- 10 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2022 and 24 closed out, a net change of -14 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2022 was Bank of America, an estimated $4.65M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2022 was PFM Health Sciences, an estimated $5.34M sold.
Based on aggregated 13F filings for Q4 2022.